MX2019004074A - Metodos para la reduccion de proteinuria en un sujeto humano que padece nefropatia por inmunoglobulina a. - Google Patents
Metodos para la reduccion de proteinuria en un sujeto humano que padece nefropatia por inmunoglobulina a.Info
- Publication number
- MX2019004074A MX2019004074A MX2019004074A MX2019004074A MX2019004074A MX 2019004074 A MX2019004074 A MX 2019004074A MX 2019004074 A MX2019004074 A MX 2019004074A MX 2019004074 A MX2019004074 A MX 2019004074A MX 2019004074 A MX2019004074 A MX 2019004074A
- Authority
- MX
- Mexico
- Prior art keywords
- nephropathy
- immunoglobulin
- methods
- human subject
- subject suffering
- Prior art date
Links
- 208000010159 IgA glomerulonephritis Diseases 0.000 title abstract 3
- 201000001474 proteinuria Diseases 0.000 title abstract 2
- 102100026046 Mannan-binding lectin serine protease 2 Human genes 0.000 abstract 2
- 101710117460 Mannan-binding lectin serine protease 2 Proteins 0.000 abstract 2
- 230000024203 complement activation Effects 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21104—Mannan-binding lectin-associated serine protease-2 (3.4.21.104)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Animal Husbandry (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Production Of Liquid Hydrocarbon Mixture For Refining Petroleum (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662407979P | 2016-10-13 | 2016-10-13 | |
US15/399,524 US10736960B2 (en) | 2016-01-05 | 2017-01-05 | Methods for inhibiting fibrosis in a subject in need thereof |
US15/470,647 US20170253667A1 (en) | 2016-01-05 | 2017-03-27 | Methods for inhibiting fibrosis in a subject in need thereof |
US201762527926P | 2017-06-30 | 2017-06-30 | |
PCT/US2017/056386 WO2018071701A1 (en) | 2016-10-13 | 2017-10-12 | Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2019004074A true MX2019004074A (es) | 2019-06-10 |
Family
ID=61906454
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019004074A MX2019004074A (es) | 2016-10-13 | 2017-10-12 | Metodos para la reduccion de proteinuria en un sujeto humano que padece nefropatia por inmunoglobulina a. |
Country Status (18)
Country | Link |
---|---|
EP (1) | EP3525798A4 (pt) |
JP (1) | JP6893554B2 (pt) |
KR (1) | KR102348939B1 (pt) |
CN (2) | CN116726163A (pt) |
AU (1) | AU2017342428B2 (pt) |
BR (1) | BR112019007426A2 (pt) |
CA (2) | CA3039927C (pt) |
CL (2) | CL2019000909A1 (pt) |
GE (1) | GEP20247587B (pt) |
IL (1) | IL265981A (pt) |
JO (1) | JOP20190068A1 (pt) |
MA (1) | MA46541A (pt) |
MX (1) | MX2019004074A (pt) |
PH (1) | PH12019500711A1 (pt) |
SG (1) | SG11201902941UA (pt) |
UA (1) | UA126908C2 (pt) |
WO (1) | WO2018071701A1 (pt) |
ZA (1) | ZA201902933B (pt) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111419860A (zh) * | 2020-03-19 | 2020-07-17 | 长春市儿童医院 | 一种肾小球分叶状肾病造模方法 |
CN115215937B (zh) * | 2021-04-15 | 2023-05-26 | 上海麦济生物技术有限公司 | 抗人masp-2抗体及其制备方法和应用 |
CN117016486B (zh) * | 2023-07-20 | 2024-05-14 | 上海澎立生技医药研究有限公司 | 一种IgA肾病合并膜性肾病的动物模型构建方法 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT2374819T (pt) * | 2003-05-12 | 2017-07-04 | Helion Biotech Aps | Anticorpos para masp-2 |
US7919094B2 (en) * | 2004-06-10 | 2011-04-05 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
US8840893B2 (en) * | 2004-06-10 | 2014-09-23 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
US20140056873A1 (en) * | 2004-06-10 | 2014-02-27 | University Of Leicester | Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation |
US7626730B2 (en) | 2006-03-31 | 2009-12-01 | Eastman Kodak Company | Method of making a multilevel halftone screen |
KR101788040B1 (ko) * | 2009-10-16 | 2017-10-19 | 오메로스 코포레이션 | Masp-2 의존성 보체 활성화의 억제에 의한 파종성 혈관내 응고의 치료 방법 |
US9102721B2 (en) * | 2011-01-21 | 2015-08-11 | Fibrogen, Inc. | Therapeutic method |
KR20210021101A (ko) * | 2011-04-08 | 2021-02-24 | 유니버시티 오브 레스터 | Masp-2 의존적 보체 활성화와 관련된 질병을 치료하는 방법 |
US9644035B2 (en) * | 2011-04-08 | 2017-05-09 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
LT2704743T (lt) * | 2011-05-04 | 2020-09-10 | Omeros Corporation | Kompozicijos, skirtos nuo masp-2 priklausančio komplemento aktyvinimo slopinimui |
NZ729747A (en) * | 2013-03-15 | 2020-03-27 | Omeros Corp | Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same |
IL283373B1 (en) * | 2013-10-17 | 2024-04-01 | Omeros Corp | Pharmaceutical preparations containing MASP-2 suppressors to suppress MASP-2-dependent complement activation and related diseases |
MY194810A (en) * | 2016-01-05 | 2022-12-16 | Omeros Corp | Methods for inhibiting fibrosis in a subject in need thereof |
JOP20170170B1 (ar) * | 2016-08-31 | 2022-09-15 | Omeros Corp | صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق |
-
2017
- 2017-06-16 JO JOP/2019/0068A patent/JOP20190068A1/ar unknown
- 2017-10-12 CA CA3039927A patent/CA3039927C/en active Active
- 2017-10-12 KR KR1020197012865A patent/KR102348939B1/ko active IP Right Grant
- 2017-10-12 CN CN202310450575.2A patent/CN116726163A/zh active Pending
- 2017-10-12 WO PCT/US2017/056386 patent/WO2018071701A1/en unknown
- 2017-10-12 CA CA3210384A patent/CA3210384A1/en active Pending
- 2017-10-12 JP JP2019520140A patent/JP6893554B2/ja active Active
- 2017-10-12 UA UAA201904866A patent/UA126908C2/uk unknown
- 2017-10-12 EP EP17861108.3A patent/EP3525798A4/en active Pending
- 2017-10-12 CN CN201780060710.5A patent/CN110177557A/zh active Pending
- 2017-10-12 BR BR112019007426A patent/BR112019007426A2/pt active Search and Examination
- 2017-10-12 GE GEAP201715070A patent/GEP20247587B/en unknown
- 2017-10-12 MX MX2019004074A patent/MX2019004074A/es unknown
- 2017-10-12 SG SG11201902941UA patent/SG11201902941UA/en unknown
- 2017-10-12 AU AU2017342428A patent/AU2017342428B2/en active Active
- 2017-10-12 MA MA046541A patent/MA46541A/fr unknown
-
2019
- 2019-04-01 PH PH12019500711A patent/PH12019500711A1/en unknown
- 2019-04-04 CL CL2019000909A patent/CL2019000909A1/es unknown
- 2019-04-11 IL IL265981A patent/IL265981A/en unknown
- 2019-05-10 ZA ZA2019/02933A patent/ZA201902933B/en unknown
- 2019-11-28 CL CL2019003485A patent/CL2019003485A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
EP3525798A1 (en) | 2019-08-21 |
AU2017342428B2 (en) | 2021-02-04 |
JP6893554B2 (ja) | 2021-06-23 |
CA3039927C (en) | 2023-10-10 |
UA126908C2 (uk) | 2023-02-22 |
CN110177557A (zh) | 2019-08-27 |
BR112019007426A2 (pt) | 2019-07-02 |
KR102348939B1 (ko) | 2022-01-12 |
IL265981A (en) | 2019-06-30 |
CN116726163A (zh) | 2023-09-12 |
JOP20190068A1 (ar) | 2019-04-01 |
CL2019000909A1 (es) | 2019-06-14 |
CL2019003485A1 (es) | 2020-04-13 |
PH12019500711A1 (en) | 2019-11-18 |
WO2018071701A1 (en) | 2018-04-19 |
KR20190063475A (ko) | 2019-06-07 |
JP2019534271A (ja) | 2019-11-28 |
CA3210384A1 (en) | 2018-04-19 |
CA3039927A1 (en) | 2018-04-19 |
SG11201902941UA (en) | 2019-05-30 |
ZA201902933B (en) | 2023-05-31 |
MA46541A (fr) | 2019-08-21 |
EP3525798A4 (en) | 2020-07-08 |
GEP20247587B (en) | 2024-01-25 |
NZ753260A (en) | 2021-11-26 |
AU2017342428A1 (en) | 2019-05-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NZ753515A (en) | Methods for treatment of cancer comprising tigit-binding agents | |
NZ738008A (en) | Tigit-binding agents and uses thereof | |
MX2019013072A (es) | Formulaciones de anticuerpos anti-lag3 y coformulaciones de anticuerpos anti-lag3 y anticuerpos anti-pd-1. | |
PH12017502165A1 (en) | Anti-tau antibodies and methods of use | |
MX2023007754A (es) | Una composicion que comprende un anticuerpo inhibidor de masp-2 para su uso en el tratamiento de la nefropatia por inmunoglobulina a (igan) dependiente de esteroides. | |
NZ727020A (en) | Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau | |
MD3549592T2 (ro) | Compoziții care conţin tulpini bacteriene | |
MX2022004834A (es) | Anticuerpos inhibidores de via del factor tisular y usos de los mismos. | |
CY1121806T1 (el) | Ιμιδαζοπυραζινονες ως αναστολεις pde1 | |
WO2014124334A3 (en) | Transthyretin antibodies and uses thereof | |
PH12018500578A1 (en) | Methods of treating inflammatory diseases | |
GB2593097B (en) | Cryptographic verification of database transactions | |
PH12019500711A1 (en) | Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy | |
MX2021005394A (es) | Co-formulaciones de anticuerpos anti-gen de activacion de linfocitos 3 (anti-lag3) y anticuerpos anti-muerte programada-1 (anti-pd-1). | |
PH12018500100A1 (en) | Antibodies that bind to sortilin and inhibit the binding of progranulin | |
MX2018008302A (es) | Anticuerpo antigrupo de diferenciacion 9 (anti-cd9) terapeutico. | |
EP4273165A3 (en) | Interferon beta antibodies and uses thereof | |
CY1122784T1 (el) | Αλογονωμενες κιναζολιν-τηf-αμινες ως αναστολεις του ρdε1 | |
EP4218817A3 (en) | Methods for treating metabolic diseases by inhibiting myostatin activation | |
EA201990903A1 (ru) | Способ уменьшения протеинурии у человека, страдающего от иммуноглобулин а нефропатии | |
MX2018004228A (es) | Anticuerpo que se une especificamente a erbb3 y uso de este. | |
GB201800986D0 (en) | Second Alzheimers treatment | |
EA202090453A3 (ru) | Антитела к cd40 | |
EP3385282A4 (en) | MONOCLONAL ANTIBODIES OPPOSED TO BAMBI AND USE FOR THE TREATMENT OF INFLAMMATORY DISEASES | |
TN2013000045A1 (en) | Anti-n3pglu amyloid beta peptide antibodies and uses thereof |